Zymeworks Other Assets from 2010 to 2025

ZYME Stock  USD 12.72  0.21  1.62%   
Zymeworks Common's Other Assets are increasing over the years with slightly volatile fluctuation. Other Assets are expected to dwindle to about 30.9 M. During the period from 2010 to 2025 Zymeworks Common Other Assets annual values regression line had geometric mean of  5,826,651 and mean square error of 146.3 T. View All Fundamentals
 
Other Assets  
First Reported
2015-12-31
Previous Quarter
27.3 M
Current Value
1
Quarterly Volatility
13.1 M
 
Yuan Drop
 
Covid
Check Zymeworks Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zymeworks Common's main balance sheet or income statement drivers, such as Interest Expense of 5.8 M, Selling General Administrative of 64.6 B or Total Revenue of 78.7 M, as well as many indicators such as Price To Sales Ratio of 13.82, Dividend Yield of 0.0 or PTB Ratio of 0.0031. Zymeworks financial statements analysis is a perfect complement when working with Zymeworks Common Valuation or Volatility modules.
  
Check out the analysis of Zymeworks Common Correlation against competitors.

Latest Zymeworks Common's Other Assets Growth Pattern

Below is the plot of the Other Assets of Zymeworks Common Stock over the last few years. It is Zymeworks Common's Other Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zymeworks Common's overall financial position and show how it may be relating to other accounts over time.
Other Assets10 Years Trend
Slightly volatile
   Other Assets   
       Timeline  

Zymeworks Other Assets Regression Statistics

Arithmetic Mean20,761,288
Geometric Mean5,826,651
Coefficient Of Variation93.30
Mean Deviation15,532,288
Median21,802,000
Standard Deviation19,371,105
Sample Variance375.2T
Range65.5M
R-Value0.80
Mean Square Error146.3T
R-Squared0.64
Significance0.0002
Slope3,245,114
Total Sum of Squares5628.6T

Zymeworks Other Assets History

202530.9 M
202439.9 M
202234.7 M
202134.4 M
202065.8 M
201921.8 M
201820 M

About Zymeworks Common Financial Statements

Zymeworks Common stakeholders use historical fundamental indicators, such as Zymeworks Common's Other Assets, to determine how well the company is positioned to perform in the future. Although Zymeworks Common investors may analyze each financial statement separately, they are all interrelated. For example, changes in Zymeworks Common's assets and liabilities are reflected in the revenues and expenses on Zymeworks Common's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Zymeworks Common Stock. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Assets39.9 M30.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:
Check out the analysis of Zymeworks Common Correlation against competitors.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.62)
Revenue Per Share
1.006
Quarterly Revenue Growth
0.833
Return On Assets
(0.15)
Return On Equity
(0.31)
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.